Document Detail


Additional Lesions Detected in Therapeutic Scans with Lu-DOTATATE Reflect Higher Affinity of (177)Lu-DOTATATE for Somatostatin Receptors.
MedLine Citation:
PMID:  21791941     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Objective: Peptide receptor-targeted radionuclide therapy (PRRT) of somatostatin receptor (SR)-expressing neuroendocrine tumors (NETs) has become an established therapeutic option in patients with advanced NETs. The aim of this study was to compare the lesion detection rate of (99m)Tc-EDDA/HYNIC-TOC, a newly developed tracer for NET imaging, with (177)Lu-DOTATATE used for PRRT. Methods: 8 patients (4 women, 4 men, age range 46-76 years) with histologically proven NETs, who showed high SR loads by (99m)Tc-EDDA/HYNIC-TOC scintigraphy, were treated with (177)Lu-DOTATATE. After treatment, all patients were subjected to whole-body scintigraphy with additional low-dose single-photon emission computed tomography (SPECT-CT) of the chest and abdomen. Results: All patients demonstrated (177)Lu-DOTATATE accumulation in all lesions previously detected by (99m)Tc- EDDA/HYNIC-TOC scintigraphy. Three patients showed additional lesions in the liver and lungs. Conclusions: SPECT-CT after (177)Lu-DOTATATE therapy may be helpful in detecting additional lesions not seen using (99m)Tc-EDDA/HYNIC-TOC. This could reflect the broader affinity of (177)Lu-DOTATATE for SRs compared with (99m)Tc-EDDA/HYNIC-TOC.
Authors:
Siroos Mirzaei; Brigitte Bastati; Rainer W Lipp; Peter Knoll; Niklas Zojer; Heinz Ludwig
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-7-25
Journal Detail:
Title:  Oncology     Volume:  80     ISSN:  1423-0232     ISO Abbreviation:  -     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-7-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0135054     Medline TA:  Oncology     Country:  -    
Other Details:
Languages:  ENG     Pagination:  326-329     Citation Subset:  -    
Copyright Information:
Copyright © 2011 S. Karger AG, Basel.
Affiliation:
Institute of Nuclear Medicine with PET Center, Wilhelminenspital, Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Optimal Techniques for mRNA Extraction from Neonatal Salivary Supernatant.
Next Document:  Ifosfamide, Carboplatin and Etoposide in Recurrent Malignant Glioma.